EULAR/ERA-EDTA 抗中性粒细胞胞质抗体相关血管炎管理推荐在疾病内容专家中的验证
该研究通过 2015 年 6 月对 158 名 EUVAS 成员进行在线调查(88 人回复,55.7%),独立评价 EULAR/ERA-EDTA 抗中性粒细胞胞质抗体相关血管炎管理推荐中每条证据的强度。EUVAS 成员与工作组投票模式总体高度一致,但在嗜酸性肉芽肿性多血管炎诱导缓解使用利妥昔单抗、以及肉芽肿性多血管炎/显微镜下多血管炎维持缓解使用甲氨蝶呤和吗替麦考酚酯的推荐上,EUVAS 成员给出的等级较低。
要点
- EUVAS 成员与工作组对 ANCA 相关血管炎管理推荐的投票模式总体高度一致。
- EUVAS 成员对 EGPA 诱导缓解使用利妥昔单抗的推荐等级较低。
- EUVAS 成员对 GPA/MPA 维持缓解使用甲氨蝶呤和吗替麦考酚酯的推荐等级较低。
核心结论
- 工作组的投票模式可代表更广泛血管炎社区的投票模式。
- 建议未来基于数据/专家的治疗指南采用此方法,尤其针对多系统疾病。
研究设计与样本
- 通过在线调查邀请 EUVAS 成员独立评价每条推荐的证据强度。
- 调查于 2015 年 6 月进行,158 名 EUVAS 成员中 88 人回复(55.7%)。
主要发现
- EUVAS 调查参与者与工作组成员的投票模式总体高度一致。
- EUVAS 成员对 EGPA 患者诱导缓解使用利妥昔单抗的推荐等级较低。
- EUVAS 成员对 GPA/MPA 患者维持缓解使用甲氨蝶呤和吗替麦考酚酯的推荐等级较低。
关键数值与推荐
- EUVAS 成员调查回复率为 55.7%(88/158)。
- EUVAS 成员对 EGPA 诱导缓解使用利妥昔单抗的推荐等级较低。
- EUVAS 成员对 GPA/MPA 维持缓解使用甲氨蝶呤和吗替麦考酚酯的推荐等级较低。
临床怎么用
- 可参考 EUVAS 成员与工作组投票模式的总体一致性来理解推荐的代表性。
- 对 EGPA 诱导缓解使用利妥昔单抗及 GPA/MPA 维持缓解使用甲氨蝶呤或吗替麦考酚酯的推荐,需注意 EUVAS 成员给出的等级较低。
局限性
- 调查回复率为 55.7%,未覆盖全部 EUVAS 成员。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The European League Against Rheumatism recommendations for the management of antineutrophil cytoplasmic antibody-associated vasculitis have been recently published. Unique to recommendation development, they were also voted on by members of a learned society. This paper explores the wider validity of the recommendations among people who self-identify as clinicians caring for patients with vasculitis. In addition to the task force, a learned society (European Vasculitis Society-EUVAS) was invited, through online survey, to rate independently the strength of evidence of each recommendation to obtain an indication of the agreement among the final target audience and ultimate end-users of the recommendations. The survey took place in June 2015. Of the 158 EUVAS members surveyed, there were 88 responses (55.7%). There was a large degree of agreement in the voting patterns between EUVAS survey participants and task force members. Notable exceptions were lower grades for the recommendation of the use of rituximab for remission induction in patients with eosinophilic granulomatosis with polyangiitis and for methotrexate and mycophenolate mofetil as remission maintenance agents in patients with granulomatosis with polyangiitis/microscopic polyangiitis by EUVAS members. These results are encouraging and suggest that the voting patterns of the task force are representative of the wider vasculitis community. We recommend future recommendations adopt this approach for data/expert-based treatment guidelines, especially for multisystem diseases.
引用
- Yates M, Watts R, Bajema I, et al. Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts. RMD Open. 2017. PMID: 28955487. doi:10.1136/rmdopen-2017-000449
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。